Go Pro
→ You’ve never seen anything like this before (From Porter & Company) (Ad)tc pixel
NASDAQ:PMCB

Nuvilex Q1 2025 Earnings Report

Nuvilex logo
$0.42 +0.04 (+9.86%)
As of 01:41 PM Eastern
This is a fair market value price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Nuvilex EPS Results

Actual EPS
$0.14
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Nuvilex Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Nuvilex Announcement Details

Quarter
Q1 2025
Date
9/16/2024
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Nuvilex Earnings Headlines

PharmaCyte Biotech, Inc. Increases Stake in TNF Pharmaceuticals Around Recent License for Breakthrough Light Speed Computing Platform for Use in Cryptocurrency Applications
September 2, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250902025594/en/pharmacyte-biotech-inc.-increases-stake-in-tnf-pharmaceuticals-around-recent-license-for-breakthrough-light-speed-computing-platform-for-use-in-cryptocurrency-applications/
PharmaCyte Biotech, Inc. Announces Closing of $7 Million Financing
August 20, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250820055624/en/PharmaCyte-Biotech-Inc.-Announces-Closing-of-7-Million-Financing/
$40,000,000,000,000
The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its entire military budget. Central banks have bought over 1,000 tonnes of gold a year for three years running, trading paper for metal.tc pixel
September 16 at 1:00 AM  |  American Alternative (Ad)
PharmaCyte Biotech, Inc. Announces $7 Million Capital Raise Led by Existing Investors
August 18, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250818528622/en/pharmacyte-biotech-inc.-announces-7-million-capital-raise-led-by-existing-investors/
MyMD Pharmaceuticals Secures Strategic Investments
May 21, 2024  |  businesswire.comhttps://www.businesswire.com/news/home/20240521024499/en/mymd-pharmaceuticals-secures-strategic-investments/
PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease
May 21, 2024  |  businesswire.comhttps://www.businesswire.com/news/home/20240521971719/en/pharmacyte-biotech-makes-7-million-strategic-investment-in-mymd-a-biopharmaceutical-company-focused-on-inflammatory-disease/
See More Nuvilex Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Nuvilex? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nuvilex and other key companies, straight to your email.

About Nuvilex

PharmaCyte Biotech, Inc., a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte. Ltd. and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex (NASDAQ:PMCB), Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.

View Nuvilex Profile
Earnings Tools